Restrata
Acera Surgical, Inc. · Decision date Oct 16, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision for Restrata, a traditional 510(k) submitted by Acera Surgical, Inc. of St. Louis, Missouri, under number K261245. The decision date is October 16, 2026, and the application was received April 16, 2026. The device falls under the classification name Absorbable Synthetic Wound Dressing with product code QSZ, and the review panel was General & Plastic Surgery. SESE denotes clearance of the 510(k), not premarket approval.
The October 16, 2026 letter describes Restrata as a sterile, single-use device intended for use in the management of wounds, and notes it may be used with the V.A.C. ULTA Negative Pressure Wound Therapy System. The record does not include the specialty field, the predicate device, or the summary of the technological comparison, so the basis for the equivalence finding is not established here. No efficacy or patient-outcome conclusions are drawn.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Unknown
- Decision date
- Oct 16, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K261245
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Acera Surgical, Inc.
- Product code
- QSZ
- Decision code
- SESE
- Decision date
- Oct 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Absorbable Synthetic Wound Dressing.
- Applicant
- Acera Surgical, Inc.
- Product code
- QSZ
- FDA device class
- U
FDA decision timeline
K261245 received
Application receipt date recorded by FDA.
K261245 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code QSZ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
HYALOMATRIXK261311 | Anika Therapeutics, Inc. | 510(k) clearance | Sep 2, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Acera Surgical, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- St. Louis, MO
Sources and methodology
- Original FDA record: K261245
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records